@article{7d4f38076d964d5c89789623247de7e6,
title = "A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women",
abstract = "Advanced glycation end products (AGEs) dysregulate adipokines and induce inflammation by binding to their adipocyte receptor (RAGE). Soluble RAGE (sRAGE) prevents AGEs/RAGE signaling. We performed a nested case–control study of the association between sRAGE, adipokines, and incident pancreatic cancer risk in the prospective Women's Health Initiative Study. We individually matched controls (n = 802) to cases (n = 472) on age, race, and blood draw date. We evaluated serum concentrations of sRAGE, adiponectin, leptin, monocyte chemotactic protein 1 (MCP1), and plasminogen activator inhibitor-1 (PAI1) using immunoassay. We used conditional logistic regression model to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for pancreatic cancer over biomarker quartiles (Q1–Q4). We used principal component analysis to create two composite biomarkers and performed a confirmatory factor analysis to examine the association between composite biomarker scores (CBS) and pancreatic cancer risk. Baseline serum sRAGE concentrations were inversely associated with pancreatic cancer risk (aORQ4 vs. Q1= 0.70, 95% CI: 0.50–0.99). High MCP1 (aOR Q4 vs. Q1= 2.55, 95% CI: 1.41–4.61) and the higher CBS including MCP1, PAI1, and leptin (aORQ4 vs. Q1= 1.82, 95% CI = 1.04–3.18) were also associated with increased pancreatic cancer risk among women with BMI <25 kg/m2 (P values for interaction <0.05). We found an inverse association between prediagnostic sRAGE concentrations and risk of incident pancreatic cancer in postmenopausal women. A proinflammatory CBS was associated with increased risk only in women with normal BMI. MCP1 was not modulated by sRAGE.",
keywords = "Biomarker, CCL2, body weight, composite biomarker, pancreatic cancer, prospective, sRAGE",
author = "White, {Donna L.} and Hoogeveen, {Ron C.} and Liang Chen and Peter Richardson and Milan Ravishankar and Preksha Shah and Lesley Tinker and Thomas Rohan and Whitsel, {Eric A.} and El-Serag, {Hashem B.} and Li Jiao",
note = "Funding Information: This work was supported by the National Cancer Institute (5R01CA172880, PI: LJ) and Houston Veterans Affairs Health Services Research Center of Innovations (CIN13-413). The women{\textquoteright}s health initiative (WHI) program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118–32119, 32122, 42107-26, 42129-32, and 44221, and the Cancer Center Support Grant NIH:NCI P30CA022453 Funding Information: We acknowledge the dedicated effort of the investigators and staff at the Women's Health Initiative (WHI) clinical centers, the WHI Clinical Coordinating Center, and the National Heart, Lung and Blood program office (listing available at http://www.whi.org). We also recognize the WHI participants for their commitment to the WHI program. For a list of all the investigators who have contributed to WHI science, please visit: http://www.whiscience.org/publications/WHI_investigators_longlist.pdf. This work was supported by the National Cancer Institute (5R01CA172880, PI: LJ) and Houston Veterans Affairs Health Services Research Center of Innovations (CIN13-413). The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118?32119, 32122, 42107-26, 42129-32, and 44221, and the Cancer Center Support Grant NIH:NCI P30CA022453. Funding Information: We acknowledge the dedicated effort of the investigators and staff at the Women{\textquoteright}s Health Initiative (WHI) clinical centers, the WHI Clinical Coordinating Center, and the National Heart, Lung and Blood program office (listing available at http://www.whi.org). We also recognize the WHI participants for their commitment to the WHI program. For a list of all the investigators who have contributed to WHI science, please visit: http://www.whiscience.org/ publications/WHI_investigators_longlist.pdf. This work was supported by the National Cancer Institute (5R01CA172880, PI: LJ) and Houston Veterans Affairs Health Services Research Center of Innovations (CIN13-413). The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118–32119, 32122, 42107-26, 42129-32, and 44221, and the Cancer Center Support Grant NIH:NCI P30CA022453. Publisher Copyright: {\textcopyright} 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2018",
month = may,
doi = "10.1002/cam4.1426",
language = "English (US)",
volume = "7",
pages = "2180--2191",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "5",
}
